Jun 11
A muy pocos días del primer episodio de #TheAppleChallenge
Inteligencia Artificial aplicada a la Uro Oncología by #Urotarget
Pensando y construyendo el futuro
Fernando Galanternik on board!
Ultimos lugares
eventbrite.com.ar/e/ia-en-ur…
1
73
May 31
Great presentation of #AI Medical education in oncology by @GarradEvan
#ASCO26 #digitalhealth #AAOCDigital @UroTarget
With trainning we improve cancer care ‼️
4
11
285
May 31
🎯🎯 #ASCO26 @ASCO Starting a Day 3 . Please don’t miss a Biomarker and perioperative management of MIUC! ➡️ Now in a S102 room! Excellent Clinical-based discussion!
@OncoAlert @urotoday @ASCOPres @GuardConsortium @UroTarget @DrRosenbergMSK @MichvdHeijden
5
10
849
May 31
#LATAM @ASCO Leadership 🥇
Great to meet with colleagues and friends committed to building a culture of collaboration to improve cancer care across Latin America. #Oncology #CancerCare #Leadership @UroTarget
1
2
9
628
May 31
🏆🏆⚽️#ASCO26 The World @ASCO Cup is running !! Peru, Brasil,USA, Colombia, Argentina are main countries involved!! Great visitors👇
👉 The tournament is running !!
@OncoAlert @aaoncoclinica @weoncologists @tompowles1 @esmo @UroTarget @DrChoueiri @SoaresAndrey @raymanneh @cloc_oncologia
1
1
11
343
May 31
🏆🏆⚽️#ASCO26 The World @ASCO Cup is running !! Peru, Brasil,USA, Colombia, Argentina are main countries involved!! Great visitors👇
👉 The tournament is running !!
@OncoAlert @aaoncoclinica @weoncologists @tompowles1 @esmo @UroTarget @DrChoueiri @SoaresAndrey @raymanneh @cloc_oncologia
3
9
361
May 30
Precision oncology is moving upstream in prostate cancer.
TALAPRO-3: Talazoparib enzalutamide reduced the risk of progression or death by 52% in patients with HRR-altered mCSPC.
Great work by @neerajaiims and all the investigators! 👏
#ASCO26 #pcsm #ProstateCancer @UroTarget
2
5
303
May 30
🎯 ##ASCO26 @ASCO TALAPRO-3 ph 3 study of ADT Enza /- talazoparib in mHSPC presented by Dr Neeraj Agarwal!
👉 TALA ENZA led to a clinically meaningful and statistically significant prolongation of rPFS (HR, 0.48) vs the active ENZA control in men with HRR gene-altered mCSPC
@OncoAlert @tompowles1 @DrChoueiri @GuardConsortium @UroTarget @neerajaiims
7
13
1,083
May 30
Not all ARPIs are the same when it comes to the brain.
In the ARACOG trial, darolutamide was associated with significantly less objectively assessed cognitive decline than enzalutamide after 24 weeks of treatment in advanced prostate cancer.
@CaPsurvivorship @UroTarget
#ASCO26
3
9
433
En el McCormick o afuera, de día o de noche, #ASCO26 no descansa…Conversando sobre Burn out, equilibrio trabajo/familia y emprendedurismo en oncología con @fedelosco
Y que mejor que con una pizza! #CHICAGO @UroTarget #applechallenge
#Radioterapia
1
1
8
343
May 30
Excited to begin my role on the #IDEAASCO Steering Committee, helping support leadership development and quality cancer care around the world. 🌎🎗️
@ASCO @UroTarget @aaoncoclinica
4
1
18
478
May 29
Nectin-4 story in Urothelial carcinoma
The past... The present and the future by @apolo_andrea
Still missing the information if resistance is a matter of the target or the payload?? @tompowles1 @ASCO #ASCO26 @UroTarget
1
4
14
804
May 29
🎯 #ASCO26 @ASCO NEXUS-01 @gopaiyer study in mUC with a new nectin4 ADC (camptho payload) MTD 3.6 mg/k?
ORR 42% (pretreated EV-Pembro)
👉 well tolerated (low diarrhea and > hematologic toxicity) @PGrivasMDPhD @OncoAlert @tompowles1 @DrChoueiri @GuardConsortium @UroTarget
14
18
1,532
May 29
Among all the strategic questions discussed today, one clearly stood above the rest: @DrChoueiri Troll.
#ASCO26
@UroTarget
1
3
199
May 29
🎯 #ASCO26 @ASCO Perioperative SHR-A2102 (nectin4) adebrelimab in MIBC ! Ph2 study @DingwelYe
👉 pCR (48%) with only 5mo follow-up (similar or less efficacy to EV-pembro) ph3 study?? @OncoAlert @tompowles1 @DrChoueiri @GuardConsortium @UroTarget @PGrivasMDPhD @apolo_andrea
8
13
755
May 29
🎯 #ASCO26 @ASCO Intravesical recombinant BCG Ch-IO (Atezo) in MIBC (SAKK 06/19) @cathomas
👉 >> pCR with the Combination of rCG plus chemo-immunotherapy is feasible and manageable!
@OncoAlert @tompowles1 @DrChoueiri @GuardConsortium @UroTarget
1
8
12
831